Bank of Nova Scotia Sells 350,967 Shares of Boston Scientific Corporation $BSX

Bank of Nova Scotia trimmed its holdings in Boston Scientific Corporation (NYSE:BSX) by 11.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,674,552 shares of the medical equipment provider’s stock after selling 350,967 shares during the period. Bank of Nova Scotia owned about 0.18% of Boston Scientific worth $261,116,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Boothbay Fund Management LLC lifted its holdings in shares of Boston Scientific by 1,079.0% during the 3rd quarter. Boothbay Fund Management LLC now owns 28,250 shares of the medical equipment provider’s stock valued at $2,758,000 after purchasing an additional 25,854 shares in the last quarter. Anchor Investment Management LLC grew its position in shares of Boston Scientific by 14.4% in the 3rd quarter. Anchor Investment Management LLC now owns 9,513 shares of the medical equipment provider’s stock valued at $929,000 after purchasing an additional 1,199 shares during the period. Aquatic Capital Management LLC bought a new stake in Boston Scientific during the 3rd quarter worth approximately $32,325,000. Arkos Global Advisors raised its holdings in Boston Scientific by 55.5% during the 3rd quarter. Arkos Global Advisors now owns 9,364 shares of the medical equipment provider’s stock worth $914,000 after buying an additional 3,341 shares during the period. Finally, 1248 Management LLC raised its holdings in Boston Scientific by 2,276.9% during the 3rd quarter. 1248 Management LLC now owns 8,224 shares of the medical equipment provider’s stock worth $803,000 after buying an additional 7,878 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $69.15 on Friday. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50. The company’s fifty day simple moving average is $82.47 and its 200-day simple moving average is $93.29. The firm has a market cap of $102.61 billion, a PE ratio of 35.64, a P/E/G ratio of 0.97 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the firm earned $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group set a $99.00 price target on shares of Boston Scientific in a report on Thursday, February 5th. Evercore dropped their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Needham & Company LLC cut their price objective on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Wells Fargo & Company reduced their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $108.00.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.